Bio-Thera Solutions Ltd.
http://www.bio-thera.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bio-Thera Solutions Ltd.
Chikungunya Vaccine, Hemophilia B Gene Therapy Among 14 Products On Track For EU Approval
The EU is on track to get its first vaccine for preventing the disease caused by chikungunya virus. Thirteen other products have also been recommended for pan-EU approval.
Sandoz And Bio-Thera Get EU Nod For Bevacizumab
At its May meeting, the EMA’s CHMP has issued positive opinions for Sandoz and Bio-Thera’s Avzivi partnered biosimilar rival to Avastin, as well as five generics that included a trio of pomalidomide products.
Bio-Thera And Stada Joins Forces On Golimumab, With Up To $160m On The Table
With European biosimilar approvals already in hand for the immunology giants adalimumab and ustekinumab, Stada has allied with Bio-Thera Solutions to bring onboard the commercialization rights for the Chinese firm’s proposed golimumab biosimilar, which currently has a limited pool of chasers.
Chinese Drug Makers Trim, Boost Pipelines In New R&D Drive
The ranks of B7-H3-targeting antibody-drug conjugates under development in China have seen their first dropout, although elsewhere there are two FGFR2b-directed ADCs with first-in-class potential on the horizon. Meanwhile, there have been other discontinuations of KRAS G12C inhibitors and anti-BCMA CAR-T cell therapies in the country, while new players have surfaced in the areas of mRNA cancer vaccines and amyloid-beta-targeting antibodies for Alzheimer’s disease.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Biotech Biopharmaceutical Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice